Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › SABS

SAB Biotherapeutics

SABS Lead: Phase 2 4 Biotech Distilled articles ↓ 28 filings & releases ↓ Cash $14.4M (Sep 30, 2026) ↓ 4 verdicts ↓
Metabolic Protein

Market cap $273M 90.1M shares (10-Q, Nov 2, 2026) × $3.03 close Nov 6, 2026

Most recent annual filing: 2026-03-09

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. SAB-142 enrollment done4Q 2026SAB-142 enrollment done, 4Q 2026, notable
  2. PRISE-hATG corporate update4Q 2026PRISE-hATG corporate update, 4Q 2026, routine
  3. SAB-142 topline2H 2027SAB-142 topline, 2H 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Technology platforms

Tc-Bovine

Transchromosomic cattle platform using engineered human artificial chromosomes to produce targeted, multi-specific human IgG (hIgG) polyclonal antibodies at scale without human plasma donors; applicable to immune/autoimmune disorders, cancer, viruses, bacteria, and toxins

Capital (as filed)

Cash
$14.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$89.6M Sep 30, 2026
Long-term investments
$101M Sep 30, 2026
Operating cash flow
−$13.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$205M cash, runway 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on SAB Biotherapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-07-16 Speculative buy speculative SAB Biotherapeutics (SABS) — Scientific Deep Dive for SAB-142 and Pipeline Products Mechanism de-risked by two human rATG RCTs, elite syndicate including strategic Sanofi, and balance sheet funded through the pivotal 2H-2027 readout justify a small catalyst-sized position despite only n=4 own-drug efficacy data and a massive warrant overhang.
  2. 2026-08-07 Speculative buy speculative UPDATE: SAB Biotherapeutics (SABS) - The Herd Gets a Backup, the Float Gets a Haircut Manufacturing redundancy (second herd + Emergent MSA), a second registrational path via PRISE-hATG, and DMC clearance into adolescents de-risk execution, but own-drug efficacy remains n=4 and the float is growing; thesis intact at small sizing.
  3. 2026-10-14 Speculative buy speculative UPDATE: SAB Biotherapeutics (SABS) - Fast Track, Same Binary FDA Fast Track designation adds procedural speed to the post-readout path and supports the accelerated-approval angle, but does nothing to the SAFEGUARD binary itself; thesis maintained at small sizing.
  4. 2026-11-06 Speculative buy speculative UPDATE: SAB Biotherapeutics (SABS) - The Last Cohort Standing Final DMC pediatric step-down clears the last safety gate and enrollment is nearly complete, but own-drug efficacy remains n=4 and the diluted share count keeps growing; thesis maintained at small sizing pending enrollment completion.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (28)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)